Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168613 | 1.00 | NNMT (0.42) | NNMTSLC6A4KCNK3KCNK9OXTR | |
| SCHEMBL498475 | 1.00 | NNMT (0.42) | NNMTSLC6A4KCNK3KCNK9OXTR | |
| SCHEMBL4572837 | 0.86 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7TUBB4A | |
| SCHEMBL14480161 | 0.84 | NNMT (0.45) | NNMTKCNK3KCNK9OXTRMKNK1 | |
| SCHEMBL998123 | 0.84 | NNMT (0.45) | NNMTKCNK3KCNK9OXTRMKNK1 | |
| SCHEMBL998124 | 0.84 | NNMT (0.45) | NNMTKCNK3KCNK9OXTRMKNK1 | |
| SCHEMBL19965687 | 0.81 | NNMT (0.41) | NNMTKCNK3KCNK9OXTRTUBB4A | |
| SCHEMBL998349 | 0.81 | NNMT (0.42) | NNMTKCNK3OXTRMKNK1MKNK2 | |
| SCHEMBL998346 | 0.81 | NNMT (0.42) | NNMTKCNK3OXTRMKNK1MKNK2 | |
| SCHEMBL6061992 | 0.81 | NNMT (0.47) | NNMTMKNK1MKNK2CHRNA7TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-05-31 | — | — | US | disclosed |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-09 | — | — | US | disclosed |
| EP-2755970-B1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20150087648-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2015-03-26 | — | — | US | disclosed |
| US-8912224-B2 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| EP-2567958-B1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI SA (FR) | 2014-10-29 | — | — | EP | disclosed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
| EP-2567958-A1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20090209767-A1 | 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20080081926-A1 | SULFONYLAMINOBENZOIC ACID AND SALT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20060142350-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20040192738-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142350-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SCN1A, KCNH1, SCN1B | NNMT 1700/4885SLC6A4 2866/4885KCNK3 84/4885 |
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | NNMT 4302/4885SLC6A4 161/4885KCNK3 294/4885 |
| US-20080081926-A1 | SULFONYLAMINOBENZOIC ACID AND SALT | SLC5A1, SLC5A2, SLC1A5 | NNMT 1459/4885SLC6A4 188/4885KCNK3 842/4885 |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | NNMT 4312/4885SLC6A4 123/4885KCNK3 301/4885 |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, RYR1 | NNMT 4185/4885SLC6A4 159/4885KCNK3 288/4885 |
| US-20090209767-A1 | 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound | KCNH1, KCNA1, SCN5A | NNMT 1441/4885SLC6A4 2196/4885KCNK3 80/4885 |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | NNMT 4302/4885SLC6A4 161/4885KCNK3 294/4885 |
| US-20150087648-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | NNMT 4312/4885SLC6A4 123/4885KCNK3 301/4885 |
| US-20040192738-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SCN1A, SCN1B, KCNH1 | NNMT 1727/4885SLC6A4 3191/4885KCNK3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.